comparemela.com

Latest Breaking News On - Genitourinary oncologist - Page 1 : comparemela.com

ASCO 2024: ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Spaces

discussed ADT-sparing approaches in both the metastatic castrate sensitive and resistant settings.

United statesNew yorkMemorial sloan kettering cancer centerKaren autioKarena autioEuropean association of urologyAmerican society of clinical oncologyOncology groupNational comprehensive cancer networkUniversity of torontoSociety of urologic oncologyGenitourinary oncologist early drug development specialistAmerican urological associationClinical oncologyAnnual meetingProstate cancer consensus conference

Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium

/PRNewswire/ Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other.

United statesUnited kingdomSan franciscoMichaell meyersGopa iyerPrnewswire flare therapeutics incMoscone west conference centerMemorial sloane kettering cancer centerGenitourinary oncologist early drug development specialistTherapeutics incCancers symposiumChief medical officerGenitourinary oncologistEarly drug development specialistMemorial sloane kettering cancerExpansion study

Here are warning signs that men age 15-35 need to know about testicular cancer

Testicular cancer is the most common cancer diagnosed in men ages 15 and 35. But too many men are waiting months before seeking help.

Fred knightSatish choudhuryYosemite national parkNational cancer instituteGenitourinary oncologistYosemite nationalTesticular cancer

vimarsana © 2020. All Rights Reserved.